BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30978560)

  • 1. Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cells.
    Wang L; Ai M; Yu J; Jin L; Wang C; Liu Z; Shu X; Tang Z; Liu K; Luo H; Guan W; Sun X; Ma X
    Eur J Med Chem; 2019 Jun; 172():154-162. PubMed ID: 30978560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines.
    Liu H; Wu B; Ge Y; Huang J; Song S; Wang C; Yao J; Liu K; Li Y; Li Y; Ma X
    Bioorg Med Chem; 2017 Dec; 25(24):6313-6321. PubMed ID: 29102081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity.
    Qu M; Liu Z; Zhao D; Wang C; Zhang J; Tang Z; Liu K; Shu X; Yuan H; Ma X
    Bioorg Med Chem; 2017 Aug; 25(15):3989-3996. PubMed ID: 28576633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
    Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
    Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, biological evaluation, and molecular docking studies of novel 2-styryl-5-nitroimidazole derivatives containing 1,4-benzodioxan moiety as FAK inhibitors with anticancer activity.
    Duan YT; Yao YF; Huang W; Makawana JA; Teraiya SB; Thumar NJ; Tang DJ; Tao XX; Wang ZC; Jiang AQ; Zhu HL
    Bioorg Med Chem; 2014 Jun; 22(11):2947-54. PubMed ID: 24792811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.
    Wang R; Chen Y; Zhao X; Yu S; Yang B; Wu T; Guo J; Hao C; Zhao D; Cheng M
    Eur J Med Chem; 2019 Dec; 183():111716. PubMed ID: 31550660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity.
    Dao P; Smith N; Tomkiewicz-Raulet C; Yen-Pon E; Camacho-Artacho M; Lietha D; Herbeuval JP; Coumoul X; Garbay C; Chen H
    J Med Chem; 2015 Jan; 58(1):237-51. PubMed ID: 25180654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity.
    Dao P; Lietha D; Etheve-Quelquejeu M; Garbay C; Chen H
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1727-1730. PubMed ID: 28284808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities.
    Wang S; Zhang RH; Zhang H; Wang YC; Yang D; Zhao YL; Yan GY; Xu GB; Guan HY; Zhou YH; Cui DB; Liu T; Li YJ; Liao SG; Zhou M
    Eur J Med Chem; 2021 Oct; 222():113573. PubMed ID: 34091209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
    Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
    Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of novel covalent inhibitors targeting focal adhesion kinase.
    Chen T; Liu Y; Shi M; Tang M; Si W; Yuan X; Wen Y; Chen L
    Bioorg Med Chem Lett; 2021 Dec; 54():128433. PubMed ID: 34757216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Novel 2,4-Dianilinopyrimidine Derivatives Containing 4-(Morpholinomethyl)phenyl and
    Han C; Shen K; Wang S; Wang Z; Su F; Wu X; Hu X; Li M; Han J; Wu L
    Molecules; 2021 Jul; 26(14):. PubMed ID: 34299462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
    Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F
    Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, biological evaluation, and molecular docking studies of novel 1,3,4-oxadiazole derivatives possessing benzotriazole moiety as FAK inhibitors with anticancer activity.
    Zhang S; Luo Y; He LQ; Liu ZJ; Jiang AQ; Yang YH; Zhu HL
    Bioorg Med Chem; 2013 Jul; 21(13):3723-9. PubMed ID: 23673215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.
    Golubovskaya VM; Nyberg C; Zheng M; Kweh F; Magis A; Ostrov D; Cance WG
    J Med Chem; 2008 Dec; 51(23):7405-16. PubMed ID: 18989950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo.
    Ucar DA; Magis AT; He DH; Lawrence NJ; Sebti SM; Kurenova E; Zajac-Kaye M; Zhang J; Hochwald SN
    Anticancer Agents Med Chem; 2013 May; 13(4):595-602. PubMed ID: 23272972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors.
    Xie H; Lin X; Zhang Y; Tan F; Chi B; Peng Z; Dong W; An D
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127459. PubMed ID: 32784087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
    Ge Y; Yang H; Wang C; Meng Q; Li L; Sun H; Zhen Y; Liu K; Li Y; Ma X
    Bioorg Med Chem; 2017 Jan; 25(2):765-772. PubMed ID: 27956037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities.
    Su Y; Li R; Ning X; Lin Z; Zhao X; Zhou J; Liu J; Jin Y; Yin Y
    Eur J Med Chem; 2019 Sep; 177():32-46. PubMed ID: 31129452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer.
    Kandil SB; Jones SR; Smith S; Hiscox SE; Westwell AD
    Molecules; 2020 Jul; 25(15):. PubMed ID: 32751931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.